Literature DB >> 3606079

Clinical efficacy and levels of ciprofloxacin in tissue in patients with soft tissue infection.

C M Licitra, R G Brooks, B E Sieger.   

Abstract

The clinical efficacy of ciprofloxacin was evaluated with 21 patients with soft tissue infection due mainly to gram-negative aerobic bacteria. Clinical cure was noted in 16 patients (76%), and clinical improvement was noted in the remaining 5 patients (24%). In addition, levels of ciprofloxacin were measured in the sera and tissues of 11 patients. Mean concentrations in tissue averaged 1.75 times the levels in serum. Ciprofloxacin should provide serum and soft tissue concentrations above the MICs for most gram-negative aerobic bacteria.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3606079      PMCID： PMC174837          DOI： 10.1128/AAC.31.5.805

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections.

Authors:  J Boerema; B Boll; H Muytjens; J Branolte
Journal:  J Antimicrob Chemother       Date:  1985-08       Impact factor: 5.790

2.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

3.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

4.  Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria.

Authors:  L J Eron; L Harvey; D L Hixon; D M Poretz
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

5.  Open, prospective study of the clinical efficacy of ciprofloxacin.

Authors:  C A Ramirez; J L Bran; C R Mejia; J F Garcia
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

6.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration.

Authors:  G Höffken; H Lode; C Prinzing; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

7.  Ciprofloxacin distribution in prostatic tissue and fluid following oral administration.

Authors:  J B Boerema; A Dalhoff; F M Debruyne
Journal:  Chemotherapy       Date:  1985       Impact factor: 2.544

8.  Tissue distribution of ciprofloxacin following oral and intravenous administration.

Authors:  A Dalhoff; H U Eickenberg
Journal:  Infection       Date:  1985 Mar-Apr       Impact factor: 3.553

9.  Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.

Authors:  M A Gonzalez; F Uribe; S D Moisen; A P Fuster; A Selen; P G Welling; B Painter
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

10.  Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.

Authors:  B E Scully; H C Neu; M F Parry; W Mandell
Journal:  Lancet       Date:  1986-04-12       Impact factor: 79.321
  10 in total
  10 in total

1.  Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients.

Authors:  M Müller; M Brunner; U Hollenstein; C Joukhadar; R Schmid; E Minar; H Ehringer; H G Eichler
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Distribution and antimicrobial activity of ciprofloxacin in human soft tissues.

Authors:  M Brunner; U Hollenstein; S Delacher; D Jäger; R Schmid; E Lackner; A Georgopoulos; H G Eichler; M Müller
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 3.  Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future.

Authors:  Christian Joukhadar; Markus Müller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

5.  Ciprofloxacin inhibits advanced glycation end products-induced adhesion molecule expression on human monocytes.

Authors:  S Mori; H K Takahashi; K Liu; H Wake; J Zhang; R Liu; T Yoshino; M Nishibori
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

6.  Tissue pharmacokinetics of levofloxacin in human soft tissue infections.

Authors:  Romuald Bellmann; Gerald Kuchling; Pejman Dehghanyar; Markus Zeitlinger; Erich Minar; Bernhard X Mayer; Markus Müller; Christian Joukhadar
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

7.  Method To Detect Only Live Bacteria during PCR Amplification.

Authors:  Takashi Soejima; Ken-ichiro Iida; Tian Qin; Hiroaki Taniai; Masanori Seki; Shin-ichi Yoshida
Journal:  J Clin Microbiol       Date:  2008-04-30       Impact factor: 5.948

Review 8.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 9.  The use of oral fluoroquinolones in nursing home patients.

Authors:  T M File; J S Tan
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.